Science Explorer Back to mapMap

Most cited papers from Istituto Oncologico Romagnolo

What are the most cited papers from Istituto Oncologico Romagnolo?

The most cited paper from Istituto Oncologico Romagnolo is "Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study" (Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al., 2009), with 2,681 citations. Next come "CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group" (2,098) and "Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results" (1,209).

Showing 50 of 59 papers. Every paper with more than 175 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology Open access 22 Feb 2009 2,681
2 CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Michael G. Pfreundschuh et al. · The Lancet Oncology 7 Apr 2006 2,098
3 Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Tim Hughes · Blood Open access 7 Mar 2006 1,209
4 International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts Hervé Dombret et al. · Blood Open access 18 May 2015 1,168
5 The P2X7 Receptor: A Key Player in IL-1 Processing and Release Davide Ferrari, Cinzia Pizzirani, Elena Adinolfi et al. · The Journal of Immunology Apr 2006 1,032
6 European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications Evangelos Terpos et al. · Haematologica Open access Oct 2015 994
7 Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Philippe Moreau, Jesús F. San Miguel, Pieter Sonneveld et al. · Annals of Oncology Open access 6 Apr 2017 882
8 Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients Stefano Aldo Pileri et al. · Leukemia 14 Dec 2006 718
9 Multipotent Mesenchymal Stem Cells with Immunosuppressive Activity Can Be Easily Isolated from Dental Pulp Laura Pierdomenico, Laura Bonsi, Mario Calvitti et al. · Transplantation 27 Sep 2005 611
10 IMWG consensus on risk stratification in multiple myeloma Wee Joo Chng, Angela Dispenzieri, C-S Chim et al. · Leukemia 26 Aug 2013 604
11 Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro Francesco Alviano, Valentina Fossati, Cosetta Marchionni et al. · BMC Developmental Biology Open access 21 Feb 2007 442
12 Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer Umberto Veronesi et al. · JNCI Journal of the National Cancer Institute 3 Nov 1999 421
13 2011: the immune hallmarks of cancer Federica Cavallo, Carla De Giovanni, Patrizia Nanni et al. · Cancer Immunology Immunotherapy Open access 25 Jan 2011 419
14 Successful Validation of the Palliative Prognostic Score in Terminally Ill Cancer Patients Marco Cesare Maltoni, Oriana Nanni, Marco Pirovano et al. · Journal of Pain and Symptom Management Open access Apr 1999 419
15 A New Palliative Prognostic Score Marco Pirovano, Marco Cesare Maltoni, Oriana Nanni et al. · Journal of Pain and Symptom Management Open access Apr 1999 418
16 Validation of a food-frequency questionnaire to assess dietary intakes in cancer studies in Italy results for specific nutrients Adriano Decarli, Silvia Franceschi, Monica Ferraroni et al. · Annals of Epidemiology Mar 1996 415
17 Coded aperture imaging in X- and gamma-ray astronomy E. Caroli, J. B. Stephen, G. Di Cocco et al. · Space Science Reviews Sep 1987 409
18 Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse Mark J. Levis et al. · Blood Open access 26 Jan 2011 405
19 An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma Thomas Elmer Witzig, Julie Marie Vose, Pier Luigi Zinzani et al. · Annals of Oncology Open access 13 Jan 2011 396
20 The effects of imatinib on pregnancy outcome Seonaid Pye, Jörge E. Cortes, Patricia S Ault et al. · Blood Open access 6 Mar 2008 396
21 Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor Alfonso Iorio, Clive Kearon, Esmeralda Filippucci et al. · Archives of Internal Medicine 25 Oct 2010 384
22 Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol Marco Vignetti, Paola Fazi, Giuseppe G. Cimino et al. · Blood Open access 9 Jan 2007 375
23 Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma Michèle Cavo, Elena Zamagni, Patrizia Tosi et al. · Blood 11 Mar 2005 370
24 Peripheral T-cell lymphoma Francine M. Foss, Pier Luigi Zinzani, Julie Marie Vose et al. · Blood Open access 15 Apr 2011 353
25 Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study Livio Pagano et al. · Haematologica Open access 22 Oct 2009 316
26 Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype Francisco J. Hernandez‐Ilizaliturri, George Michael Deeb, Pier Luigi Zinzani et al. · Cancer 14 Apr 2011 308
27 Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Monica Santimaria, Giovanni Moscatelli, Giuseppe Viale et al. · PubMed Feb 2003 294
28 Exercises for paretic upper limb after stroke: A combined virtual-reality and telemedicine approach L. Piron, Andrea Turolla, Michela Agostini et al. · Journal of Rehabilitation Medicine Open access 2009 282
29 Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR Andrew G Spencer et al. · Haematologica Open access 20 Sep 2018 262
30 Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia Francesco F. Zaja et al. · Blood 3 Feb 2010 262
31 Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer Sabina Signoretti, Lucia Di Marcotullio, Andrea L. Richardson et al. · Journal of Clinical Investigation Open access Sep 2002 256
32 Reproducibility of an Italian food frequency questionnaire for cancer studies Silvia Franceschi, Fabio Barbone, Eva Negri et al. · Annals of Epidemiology 1995 246
33 Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group Heinz Ludwig et al. · Blood Open access 12 Feb 2008 234
34 Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens Shaji Kunnathu Kumar et al. · Blood Open access 27 Jun 2009 234
35 Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy Simona Soverini, Manuela Mancini, Luana Bavaro et al. · Molecular Cancer Open access 15 Feb 2018 232
36 Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis Sara Trabanelli et al. · Nature Communications Open access 13 Sep 2017 232
37 International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) Sergio A. Giralt et al. · Leukemia 25 Jun 2009 232
38 Altered pre-lamin A processing is a common mechanism leading to lipodystrophy Cristina Capanni, Elisabetta Mattioli, Marta Columbaro et al. · Human Molecular Genetics 20 Apr 2005 226
39 Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients Pier Luigi Zinzani, Gianandrea Baliva, Massimo Magagnoli et al. · Journal of Clinical Oncology Jul 2000 226
40 Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study Michael G. Pfreundschuh, Anthony Dick Ho, Eva K. Cavallin-Ståhl et al. · The Lancet Oncology 8 Apr 2008 223
41 Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP) Ilaria Iacobucci et al. · Blood Open access 10 Jul 2009 222
42 European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma Monika Martha Engelhardt et al. · Haematologica Open access Feb 2014 213
43 Impact of delirium on the short term prognosis of advanced cancer patients Augusto Tommaso Caraceni, Oriana Nanni, Marco Cesare Maltoni et al. · Cancer Sep 2000 204
44 Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase Jörge E. Cortes et al. · Leukemia 28 Aug 2008 201
45 Prediction of survival of patients terminally III with cancer. Results of an Italian prospective multicentric study Marco Cesare Maltoni, Marco Pirovano, Emanuela Scarpi et al. · Cancer Open access 15 May 1995 197
46 Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome Pier Luigi Zinzani, Filippo Venturini, Vittorio Stefoni et al. · Annals of Oncology Open access 4 Nov 2009 196
47 Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Haematologica Open access Mar 2007 191
48 Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation Franck Morschhauser, Tim Illidge, Damien G. Huglo et al. · Blood 26 Mar 2007 187
49 Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti et al. · Journal of Clinical Oncology Open access 9 Aug 2019 185
50 Food groups and risk of colorectal cancer in Italy Silvia Franceschi, Adriano Favero, Carlo La Vecchia et al. · International Journal of Cancer 3 Jul 1997 185

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.